Frequency and determinants of serum calcium monitoring during eldecalcitol therapy in patients with osteoporosis

被引:3
作者
Ri, Kairi [1 ]
Fukasawa, Toshiki [1 ,2 ]
Masuda, Soichiro [1 ,3 ]
Tanaka, Shiro [4 ]
Takeuchi, Masato [1 ]
Yoshida, Satomi [1 ]
Kawakami, Koji [1 ]
机构
[1] Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Pharmacoepidemiol, Kyoto, Japan
[2] Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Digital Hlth & Epidemiol, Yoshidakonoe Cho, Sakyo Ku, Kyoto 6068501, Japan
[3] Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Kyoto, Japan
[4] Kyoto Univ, Grad Sch Med, Dept Clin Biostat, Kyoto, Japan
关键词
Eldecalcitol; Hypercalcemia; Monitoring; Osteoporosis; Vitamin D; HYPERCALCEMIA; ANALOG; RISK;
D O I
10.1007/s00774-023-01470-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionEldecalcitol (ELD) is an active vitamin D3 analog (AVD) commonly used to treat osteoporosis in Japan. Although routine monitoring of serum calcium levels during ELD therapy is recommended, little is known about the actual frequency and determinants of monitoring.Materials and methodsThis was a descriptive cohort study using a Japanese electronic medical records database. We identified osteoporosis patients who initiated treatment with ELD or other AVDs (alfacalcidol and calcitriol) between April 1, 2011 and September 10, 2021. The index date for cohort entry was the first prescription date of ELD or other AVDs. The frequency of serum calcium monitoring was evaluated every 6 months. Determinants of serum calcium monitoring were identified using multivariable logistic regression models. We also calculated the incidence of hypercalcemia and the frequency of serum calcium monitoring within 6 months before hypercalcemia.ResultsWe identified 12,671 ELD users and 7867 other AVD users. Within 6 months after cohort entry, 45.9% of ELD users and 58.7% of other AVD users underwent serum calcium monitoring. Female sex, no use of systemic corticosteroids, moderate-to-good renal function, treatment in smaller hospitals, and treatment in orthopedic surgery departments were associated with a lower likelihood of receiving serum calcium monitoring during ELD therapy. The incidence of hypercalcemia among ELD users was 6.36 per 100 person-years, with 20.6% of cases not receiving serum calcium monitoring before hypercalcemia.ConclusionOur findings suggest that serum calcium monitoring is not given adequate attention during ELD therapy in routine clinical practice.
引用
收藏
页码:890 / 900
页数:11
相关论文
共 24 条
[1]   Hypercalcemia and acute kidney injury induced by eldecalcitol in patients with osteoporosis: a case series of 32 patients at a single facility [J].
Aihara, Seishi ;
Yamada, Shunsuke ;
Oka, Hideaki ;
Kamimura, Taro ;
Nakano, Toshiaki ;
Tsuruya, Kazuhiko ;
Harada, Atsumi .
RENAL FAILURE, 2019, 41 (01) :88-97
[2]  
[Anonymous], 2003, Am J Kidney Dis, V42, P1
[3]   Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples [J].
Austin, Peter C. .
STATISTICS IN MEDICINE, 2009, 28 (25) :3083-3107
[4]   Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis [J].
Cui, Lijia ;
Xia, Weibo ;
Yu, Chuan ;
Dong, Shuangshuang ;
Pei, Yu .
ARCHIVES OF OSTEOPOROSIS, 2022, 17 (01)
[5]   Predictors for self-discontinuation of anti-osteoporosis medication: A hospital-based real-world study [J].
Deng, Ya-Lian ;
Hsu, Chun-Sheng ;
Hsu, Chiann-Yi ;
Chen, Chih-Hui ;
Ou, Shiang-Ferng ;
Liu, Chin-Feng ;
Yang, Shu-Hui ;
Shih, Chun-Hsi ;
Chen, Yi-Ming ;
Lee, Hsu-Tung .
PLOS ONE, 2022, 17 (09)
[6]  
Fujiwara S, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657-018-0443-7
[7]   Association between biopsies for anti-neutrophil cytoplasmic antibody-associated vasculitis and prognosis: a retrospective cohort study [J].
Hashimoto, Hiroyuki ;
Takeuchi, Masato ;
Kawakami, Koji .
CLINICAL RHEUMATOLOGY, 2022, 41 (02) :541-548
[8]   Vitamin D in Chronic Kidney Disease and Dialysis Patients [J].
Jean, Guillaume ;
Souberbielle, Jean Claude ;
Chazot, Charles .
NUTRIENTS, 2017, 9 (04)
[9]   KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Foreword [J].
Wheeler, David C. ;
Winkelmayer, Wolfgang C. .
KIDNEY INTERNATIONAL SUPPLEMENTS, 2017, 7 (01) :12-12
[10]   Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis A Population-Based Cohort Study [J].
Lyu, Houchen ;
Yoshida, Kazuki ;
Zhao, Sizheng S. ;
Wei, Jie ;
Zeng, Chao ;
Tedeschi, Sara K. ;
Leder, Benjamin Z. ;
Lei, Guanghua ;
Tang, Peifu ;
Solomon, Daniel H. .
ANNALS OF INTERNAL MEDICINE, 2020, 173 (07) :516-+